1
|
Cao Z, Zhang K, Liu J, Pan Y, Shi J, Li L, Sun X, Li S, Yuan X, Wu D. F127-SE-tLAP thermosensitive hydrogel alleviates bleomycin-induced skin fibrosis via TGF-β/Smad pathway. Mol Med 2024; 30:52. [PMID: 38641575 PMCID: PMC11031956 DOI: 10.1186/s10020-024-00815-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2024] [Accepted: 03/30/2024] [Indexed: 04/21/2024] Open
Abstract
BACKGROUND Skin fibrosis affects the normal function of the skin. TGF-β1 is a key cytokine that affects organ fibrosis. The latency-associated peptide (LAP) is essential for TGF-β1 activation. We previously constructed and prepared truncated LAP (tLAP), and confirmed that tLAP inhibited liver fibrosis by affecting TGF-β1. SPACE peptide has both transdermal and transmembrane functions. SPACE promotes the delivery of macromolecules through the stratum corneum into the dermis. This study aimed to alleviate skin fibrosis through the delivery of tLAP by SPACE. METHODS The SPACE-tLAP (SE-tLAP) recombinant plasmid was constructed. SE-tLAP was purified by nickel affinity chromatography. The effects of SE-tLAP on the proliferation, migration, and expression of fibrosis-related and inflammatory factors were evaluated in TGF-β1-induced NIH-3T3 cells. F127-SE-tLAP hydrogel was constructed by using F127 as a carrier to load SE-tLAP polypeptide. The degradation, drug release, and biocompatibility of F127-SE-tLAP were evaluated. Bleomycin was used to induce skin fibrosis in mice. HE, Masson, and immunohistochemistry were used to observe the skin histological characteristics. RESULTS SE-tLAP inhibited the proliferation, migration, and expression of fibrosis-related and inflammatory factors in NIH-3T3 cells. F127-SE-tLAP significantly reduced ECM production, collagen deposition, and fibrotic pathological changes, thereby alleviating skin fibrosis. CONCLUSION F127-SE-tLAP could increase the transdermal delivery of LAP, reduce the production and deposition of ECM, inhibit the formation of dermal collagen fibers, and alleviate the progression of skin fibrosis. It may provide a new idea for the therapy of skin fibrosis.
Collapse
Affiliation(s)
- Zhiqin Cao
- Heilongjiang Province Key Laboratory of Anti-fibrosis Biotherapy, Mudanjiang Medical University, No. 3, Tongxiang Street, Aimin District, 157011, Mudanjiang, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, 157011, Mudanjiang, Heilongjiang, China
| | - Keke Zhang
- Heilongjiang Province Key Laboratory of Anti-fibrosis Biotherapy, Mudanjiang Medical University, No. 3, Tongxiang Street, Aimin District, 157011, Mudanjiang, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, 157011, Mudanjiang, Heilongjiang, China
| | - Jingruo Liu
- Heilongjiang Province Key Laboratory of Anti-fibrosis Biotherapy, Mudanjiang Medical University, No. 3, Tongxiang Street, Aimin District, 157011, Mudanjiang, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, 157011, Mudanjiang, Heilongjiang, China
| | - Yu Pan
- Heilongjiang Province Key Laboratory of Anti-fibrosis Biotherapy, Mudanjiang Medical University, No. 3, Tongxiang Street, Aimin District, 157011, Mudanjiang, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, 157011, Mudanjiang, Heilongjiang, China
| | - Jiayi Shi
- Heilongjiang Province Key Laboratory of Anti-fibrosis Biotherapy, Mudanjiang Medical University, No. 3, Tongxiang Street, Aimin District, 157011, Mudanjiang, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, 157011, Mudanjiang, Heilongjiang, China
| | - Luxin Li
- Heilongjiang Province Key Laboratory of Anti-fibrosis Biotherapy, Mudanjiang Medical University, No. 3, Tongxiang Street, Aimin District, 157011, Mudanjiang, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, 157011, Mudanjiang, Heilongjiang, China
| | - Xiaocan Sun
- Heilongjiang Province Key Laboratory of Anti-fibrosis Biotherapy, Mudanjiang Medical University, No. 3, Tongxiang Street, Aimin District, 157011, Mudanjiang, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, 157011, Mudanjiang, Heilongjiang, China
| | - Shiqi Li
- Heilongjiang Province Key Laboratory of Anti-fibrosis Biotherapy, Mudanjiang Medical University, No. 3, Tongxiang Street, Aimin District, 157011, Mudanjiang, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, 157011, Mudanjiang, Heilongjiang, China
| | - Xiaohuan Yuan
- Heilongjiang Province Key Laboratory of Anti-fibrosis Biotherapy, Mudanjiang Medical University, No. 3, Tongxiang Street, Aimin District, 157011, Mudanjiang, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, 157011, Mudanjiang, Heilongjiang, China
| | - Dan Wu
- Heilongjiang Province Key Laboratory of Anti-fibrosis Biotherapy, Mudanjiang Medical University, No. 3, Tongxiang Street, Aimin District, 157011, Mudanjiang, Heilongjiang, China.
- College of Life Sciences, Mudanjiang Medical University, 157011, Mudanjiang, Heilongjiang, China.
| |
Collapse
|
2
|
Qiu Y, Song X, Liu Y, Wu Y, Shi J, Zhang F, Pan Y, Cao Z, Zhang K, Liu J, Chu Y, Yuan X, Wu D. Application of recombinant TGF-β1 inhibitory peptide to alleviate isoproterenol-induced cardiac fibrosis. Appl Microbiol Biotechnol 2023; 107:6251-6262. [PMID: 37606791 DOI: 10.1007/s00253-023-12722-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Revised: 07/26/2023] [Accepted: 08/06/2023] [Indexed: 08/23/2023]
Abstract
Cardiac fibrosis is a remodeling process of the cardiac interstitium, characterized by abnormal metabolism of the extracellular matrix, excessive accumulation of collagen fibers, and scar tissue hyperplasia. Persistent activation and transdifferentiation into myofibroblasts of cardiac fibroblasts promote the progression of fibrosis. Transforming growth factor-β1 (TGF-β1) is a pivotal factor in cardiac fibrosis. Latency-associated peptide (LAP) is essential for activating TGF-β1 and its binding to the receptor. Thus, interference with TGF-β1 and the signaling pathways using LAP may attenuate cardiac fibrosis. Recombinant full-length and truncated LAP were previously constructed, expressed, and purified. Their effects on cardiac fibrosis were investigated in isoproterenol (ISO)-induced cardiac fibroblasts (CFs) and C57BL/6 mice. The study showed that LAP and tLAP inhibited ISO-induced CF activation, inflammation, and fibrosis, improved cardiac function, and alleviated myocardial injury in ISO-induced mice. LAP and tLAP alleviated the histopathological alterations and inhibited the elevated expression of inflammatory and fibrosis-related markers in cardiac tissue. In addition, LAP and tLAP decreased the ISO-induced elevated expression of TGF-β, αvβ3, αvβ5, p-Smad2, and p-Smad3. The study indicated that LAP and tLAP attenuated ISO-induced cardiac fibrosis via suppressing TGF-β/Smad pathway. This study may provide a potential approach to alleviate cardiac fibrosis. KEY POINTS: • LAP and tLAP inhibited ISO-induced CF activation, inflammation, and fibrosis. • LAP and tLAP improved cardiac function and alleviated myocardial injury, inflammation, and fibrosis in ISO-induced mice. • LAP and tLAP attenuated cardiac fibrosis via suppressing TGF-β/Smad pathway.
Collapse
Affiliation(s)
- Yufei Qiu
- Heilongjiang Province Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical University, No.3, Tongxiang Street, Aimin District, Mudanjiang, 157011, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, Mudanjiang, 157011, Heilongjiang, China
| | - Xudong Song
- Heilongjiang Province Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical University, No.3, Tongxiang Street, Aimin District, Mudanjiang, 157011, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, Mudanjiang, 157011, Heilongjiang, China
| | - Yong Liu
- Heilongjiang Province Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical University, No.3, Tongxiang Street, Aimin District, Mudanjiang, 157011, Heilongjiang, China
- Center for Comparative Medicine, Mudanjiang Medical University, Mudanjiang, 157011, Heilongjiang, China
| | - Yan Wu
- Heilongjiang Province Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical University, No.3, Tongxiang Street, Aimin District, Mudanjiang, 157011, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, Mudanjiang, 157011, Heilongjiang, China
| | - Jiayi Shi
- Heilongjiang Province Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical University, No.3, Tongxiang Street, Aimin District, Mudanjiang, 157011, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, Mudanjiang, 157011, Heilongjiang, China
| | - Fan Zhang
- Heilongjiang Province Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical University, No.3, Tongxiang Street, Aimin District, Mudanjiang, 157011, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, Mudanjiang, 157011, Heilongjiang, China
| | - Yu Pan
- Heilongjiang Province Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical University, No.3, Tongxiang Street, Aimin District, Mudanjiang, 157011, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, Mudanjiang, 157011, Heilongjiang, China
| | - Zhiqin Cao
- Heilongjiang Province Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical University, No.3, Tongxiang Street, Aimin District, Mudanjiang, 157011, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, Mudanjiang, 157011, Heilongjiang, China
| | - Keke Zhang
- Heilongjiang Province Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical University, No.3, Tongxiang Street, Aimin District, Mudanjiang, 157011, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, Mudanjiang, 157011, Heilongjiang, China
| | - Jingruo Liu
- Heilongjiang Province Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical University, No.3, Tongxiang Street, Aimin District, Mudanjiang, 157011, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, Mudanjiang, 157011, Heilongjiang, China
| | - Yanhui Chu
- Heilongjiang Province Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical University, No.3, Tongxiang Street, Aimin District, Mudanjiang, 157011, Heilongjiang, China
- College of Life Sciences, Mudanjiang Medical University, Mudanjiang, 157011, Heilongjiang, China
| | - Xiaohuan Yuan
- Heilongjiang Province Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical University, No.3, Tongxiang Street, Aimin District, Mudanjiang, 157011, Heilongjiang, China.
- Center for Comparative Medicine, Mudanjiang Medical University, Mudanjiang, 157011, Heilongjiang, China.
| | - Dan Wu
- Heilongjiang Province Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical University, No.3, Tongxiang Street, Aimin District, Mudanjiang, 157011, Heilongjiang, China.
- College of Life Sciences, Mudanjiang Medical University, Mudanjiang, 157011, Heilongjiang, China.
| |
Collapse
|